Development of the first urinary reproductive hormone ranges referenced to independently determined ovulation day

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 7, 2015, Pages 1099-1108

  Johnson, Sarah ^a   Weddell, Sarah ^a   Godbert, Sonya ^a   Freundl, Guenter ^b   Roos, Judith ^b   Gnoth, Christian ^b  

^a SPD Development Company Limited   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Estrone 3 glucuronide; follicle stimulating hormone; hormone ranges; luteinising hormone; menstrual cycle; ovulation; pregnanediol 3 glucuronide

Indexed keywords

ESTRONE GLUCURONIDE; FOLLITROPIN; LUTEINIZING HORMONE; PREGNANEDIOL 3 GLUCURONIDE; PROGESTERONE; SEX HORMONE; UNCLASSIFIED DRUG; HORMONE;

ADULT; ARTICLE; FEMALE; HORMONE DETERMINATION; HORMONE URINE LEVEL; HUMAN; LUTEINIZING HORMONE RELEASE; MENSTRUAL CYCLE; NORMAL HUMAN; OVARY FOLLICLE; OVULATION; PRIORITY JOURNAL; PROGESTERONE URINE LEVEL; REFERENCE VALUE; TRANSVAGINAL ECHOGRAPHY; URINALYSIS; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; STANDARDS; URINE;

ADOLESCENT; ADULT; FEMALE; HORMONES; HUMANS; OVULATION; REFERENCE VALUES; URINALYSIS; YOUNG ADULT;

EID: 84930805676     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-1087     Document Type: Article

References (43)

1. Balasch J, Gratacós E. Delayed childbearing: effects on fertility and the outcome of pregnancy. Fetal Diagn Ther 2011;29:263-73.
2. Heffner LJ. Advanced maternal age-how old is too old N Engl J Med 2004;351:1924-9.
3. Committee opinion No. 589. Female age-related fertility decline. Fertil Steril 2014;101:633-4.
4. Lundsberg LS, Pal L, Gariepy AM, Xu X, Chu MC, Illuzzi LJ. Knowledge, attitudes, and practices regarding conception and fertility: a population-based survey among reproductive-age United States women. Fertil Steril 2014;101:767-74.
5. Gnoth C, Frank-Herrmann P, Schmoll A, Godehardt E, Freundl G. Cycle characteristics after discontinuation of oral contraceptives. Gynecol Endocrinol 2002;16:307-17.
6. Zinaman M, Johnson S, Ellis J, Ledger W. Accuracy of perception of ovulation day in women trying to conceive. CMRO 2012;28:1-6.
7. Johnson SR, Miro F, Barrett S, Ellis J. Levels of urinary human chorionic gonadotrophin (hCG) following conception and vari ability of the menstrual cycle in a cohort of women attempting to conceive. CMRO 2009;25:741-8.
8. Creinin MD, Keverline S, Meyn LA. How regular is regular An analysis of menstrual cycle regularity. Contraception 2004;70:289-92.
9. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. N Engl J Med 1995;333:1517-21.
10. Liu Y, Johnson WO, Gold EB, Lasley BL. Bayesian analysis of risk factors for anovulation. Stat Med 2004;23:1901-19.
11. Hambridge H, Mumford SL, Mattison DR, Ye A, Pollack AZ, Bloom MS, et al. The influence of sporadic anovulation on hormone levels in ovulatory cycles. Hum Reprod 2013;28:1687-94.
12. Collins WP. The evolution of reference methods to monitor ovulation. Am J Obstet Gynecol 1991;165:1994-6.
13. Kassam A, Overstreet JW, Snow-Harter C, De Souza MJ, Gold EB, Lasley BL. Identification of anovulation and transient luteal function using a urinary pregnanediol-3-glucuronide ratio algorithm. Environ Health Perspect 1996;104:408-13.
14. Blackwell LF, Vigil P, Cooke DG, d'Arcangues C, Brown JB. Monitoring of ovarian activity by daily measurement of urinary excretion rates of oestrone glucuronide and pregnanediol glucuronide using the Ovarian Monitor, Part III: variability of normal menstrual cycle profiles. Hum Reprod 2013;28:3306-15.
15. Stricker R, Eberhart R, Chevailler M, Quinn F, Bischof P, Stricker R. Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyser. Clin Chem Lab Med 2006;44:883-7.
16. Seibel M. Luteinizing hormone and ovulation timing. J Reprod Med 1986;31:754-9.
17. Direito A, Bailly S, Mariani A, Ecochard R. Relationships between the luteinizing hormone surge and other characteristics of the menstrual cycle in normally ovulating women. Fertil Steril 2013;99:279-85.
18. Ecochard R, Leiva R, Bouchard T, Boehringer H, Direito A, Mariani A, et al. Use of urinary pregnanediol 3-glucuronide to confirm ovulation. Steroids 2013;78:1035-40.
19. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. On behalf of the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011;377:557-67.
20. Hahn KA, Wise LA, Riis AH, Mikkelsen EM, Rothman KJ, Banholzer K, et al. Correlates of menstrual cycle characteristics among nulliparous Danish women. Clin Epidemiol 2013;5:311-9.
21. Kerin JF, Edmonds D, Warnes G, Cox L, Seamark R, Mathews C, et al. Morphological and functional relations of Graafian follicle growth to ovulation in women using ultrasonic, laparoscopic and biochemical measurements. Br J Obstet Gynecol 1981;88:81-90.
22. Neven P, Iles RK, Howes I, Sharma K, Shepherd JH, Edwards R, et al. Substantial urinary concentrations of material resembling-core fragment of chorionic gonadrotropin-subunit in midmenstrual cycle. Clin Chem 1993;39:1857-60.
23. O'Connor JF, Kovalevskaya G, Birken S, Schlatterer JP, Schechter D, McMahon DJ, et al. The expression of the urinary forms of human luteinizing hormone beta fragment in various popula tions as assessed by a specific immunoradiometric assay. Hum Reprod 1998;13:826-35.
24. Kurowska E, Szewczuk A. Isolation of human lutropin from woman urine and comparison of its properties with pituitary hormone. Arch Immunol Ther Exp 1999;47:179-83.
25. Birken S, Gawinowiz MA, Maydelman Y, Migrom Y. Metabolism of gonadotropins: comparison of the primary structures of the human pituitary and urinary LHcores and the chimpanzee CG core demonstrates universality of core production. J Endocrinol 2001;171:131-41.
26. Park SJ, Goldsmith LT, Skurnick JH, Wojtczuk A, Weiss G. Characteristics of the urinary luteinizing hormone surge in young ovulatory women. Fert Steril 2007;88:684-90.
27. Ecochard R, Boehringer H, Rabilloud M, Marret H. Chronological aspects of ultrasonic, hormonal, and other indirect indices of ovulation. Br J Obstet Gynecol 2001;108:822-9.
28. Elkind-Hirsch K, Goldzieher JW, Gibbons WE, Besch PK. Evaluation of the Ovustick urinary luteinizing hormone kit in normal and stimulated menstrual cycles. Obstet Gynecol 1986;67:450-3.
29. Gudgeon K, Leader L, Howard B. Evaluation of the accuracy of the home ovulation detection kit, Clearplan, at predicting ovulation. Med J Aust 1990;152:345-9.
30. Guermandi E, Vegetti W, Bianchi MM, Uglietti A, Ragni G, Crosignani P. Reliability of ovulation tests in infertile women. Obstet Gynecol 2001;97:92-6.
31. Leiva R, Burhan U, Kyrillos E, Fehring R, McLaren R, Dalzell C, et al. Use of ovulation predictor kits as adjuncts when using fertility awareness methods (FAMs): a pilot study. J Am Board Fam Med 2014;27:427-9.
32. Miller PB, Soules MR. Ovulation prediction during menstrual cycles of normal women. Obstet Gynecol 1996;87:13-7.
33. Cervinski MA, Gronowski AM. Reproductive-endocrine point-ofcare testing: current status and limitations. Clin Chem Lab Med 2010;48:935-42.
34. Behre HM, Kuhlage J, Gassner C, Sonntage B, Schem C, Schneider HP, et al. Prediction of ovulation by urinary hormone measurements with the home use Clearblue Fertility Monitor: comparison with transvaginal ultrasound scans and serum hormone measurements. Hum Reprod 2000;12:2478-82.
35. Robinson J, Wakelin M, Ellis J. Increased pregnancy rate with use of Clearblue Easy Fertility Monitor. Fertil Steril 2007;87:329-34.
36. Gronowski AM, Grenache DG, Markenson G, Weiner R, Demers LM, St. Louis P. Evidence-based practice for point-of-care testing. In: Nichols JH, editor. Reproductive testing. Washington, DC: American Association for Clinical Chemistry (AACC) Press, 2006.
37. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-8.
38. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9.
39. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11.
40. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.
41. Miro F, Coley J, Gani MM, Perry PW, Talbot D, Aspinall LJ. Comparison between creatinine and pregnanediol adjustments in the retrospective analysis of urinary hormone profiles during the human menstrual cycle. Clin Chem Lab Med 2004;42:1043-50.
42. Zacur H, Kaufman SC, Smith B, Wshoff C, Helbig D, Lee YJ, et al. Does creatinine adjustment of urinary pregnanediol glucuronide reduce or introduce measurement error Gynecol Endocrinol 1997;11:29-33.
43. Marsh EE, Shaw ND, Klingman KM, Tiamfook-Morgan TO, Yialamas MA, Sluss PM, et al. Estrogen levels are higher across the menstrual cycle in African-American women compared with Caucasian women. J Clin Endocrinol Metab 2011;96:3199-206.